Additional data demands delay Biomarin's hemophilia drug submission in US

The US health authority has requested more data pertaining to the company’s hemophilia A treatment candidate, and Biomarin has subsequently postponed its marketing approval submission.
Photo: Manuel Balce Ceneta/AP/Ritzau Scanpix
Photo: Manuel Balce Ceneta/AP/Ritzau Scanpix
by mikkel aabenhus hemmingsen, translated by daniel pedersen

Gene therapy valoctocogene roxaparvovec will not be up for re-evaluation by the US Food and Drug Administration (FDA) until September, biotech firm Biomarin has announced in a press release.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading